{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:53Z","timestamp":1792791953194,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"am","delay-in-days":296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011045","name":"Ministere de l&apos;Enseignement superieur de la Recherche et de l&apos;Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011045","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012948","name":"Minist\u00e8re de l&apos;Enseignement sup\u00e9rieur, de la Recherche et de l&apos;Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["02(0400)\/21\/EMR-II"],"award-info":[{"award-number":["02(0400)\/21\/EMR-II"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific and Industrial Research, India","doi-asserted-by":"publisher","award":["09\/254(0257)\/2016-EMR-I"],"award-info":[{"award-number":["09\/254(0257)\/2016-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejmech.2022.114531","type":"journal-article","created":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T11:11:02Z","timestamp":1655464262000},"page":"114531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis"],"prefix":"10.1016","volume":"239","author":[{"given":"Matth\u00e9o","family":"Alcaraz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharvi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Roquet-Ban\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2152-3460","authenticated-orcid":false,"given":"Cyril","family":"Conde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4351-2367","authenticated-orcid":false,"given":"Thierry","family":"Cochard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-6158","authenticated-orcid":false,"given":"Franck","family":"Biet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-7161","authenticated-orcid":false,"given":"Vipan","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-4458","authenticated-orcid":false,"given":"Laurent","family":"Kremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114531_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30038-0","article-title":"Reconsidering Mycobacterium bovis as a proxy for zoonotic tuberculosis: a molecular epidemiological surveillance study","volume":"1","author":"Duffy","year":"2020","journal-title":"Lancet Microbe"},{"issue":"21","key":"10.1016\/j.ejmech.2022.114531_bib4","first-page":"S1473","article-title":"GBD 2019 Tuberculosis Collaborators, Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114531_bib5","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"15","author":"Dheda","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2022.114531_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.drudis.2020.02.003","article-title":"The quest for the holy grail: new antitubercular chemical entities, targets and strategies","volume":"25","author":"Husz\u00e1r","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114531_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/nature09657","article-title":"The challenge of new drug discovery for tuberculosis","volume":"469","author":"Koul","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114531_bib8","doi-asserted-by":"crossref","first-page":"10583","DOI":"10.1021\/acs.jmedchem.9b01716","article-title":"Changing the rules of TB-drug discovery","volume":"62","author":"Harrison","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib9","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/acsinfecdis.7b00255","article-title":"The expanding diversity of Mycobacterium tuberculosis drug targets","volume":"4","author":"Wellington","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114531_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112175","article-title":"Repurposed drug candidates for antituberculosis therapy","volume":"192","author":"An","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115973","article-title":"A comprehensive review on the biological interest of quinoline and its derivatives","volume":"32","author":"Matada","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":"Diarylquinolines target subunit c of mycobacterial ATP synthase","volume":"3","author":"Koul","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114531_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.tube.2014.04.001","article-title":"Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls","volume":"94","author":"Kakkar","year":"2014","journal-title":"Tuberculosis"},{"key":"10.1016\/j.ejmech.2022.114531_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bmcl.2018.11.002","article-title":"Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety","volume":"29","author":"Shruthi","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114531_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.8284673","article-title":"inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis","volume":"263","author":"Banerjee","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114531_bib16","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1365-2958.2007.05761.x","article-title":"The Mycobacterium tuberculosis FAS-II condensing enzymes: their role in mycolic acid biosynthesis, acid-fastness, pathogenesis and in future drug development","volume":"64","author":"Bhatt","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2022.114531_bib17","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1128\/JB.182.14.4059-4067.2000","article-title":"Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis","volume":"182","author":"Vilch\u00e8ze","year":"2000","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.ejmech.2022.114531_bib18","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1074\/jbc.272.5.2834","article-title":"Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis","volume":"272","author":"Johnsson","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib19","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/358591a0","article-title":"The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis","volume":"358","author":"Zhang","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114531_bib20","first-page":"98","article-title":"Modification of the NADH of the isoniazid target (InhA) from","volume":"279","author":"Rozwarski","year":"1998","journal-title":"Mycobacterium tuberculosis, Science"},{"key":"10.1016\/j.ejmech.2022.114531_bib21","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/(SICI)1521-3773(19990903)38:17<2588::AID-ANIE2588>3.0.CO;2-8","article-title":"Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid","volume":"38","author":"Wilming","year":"1999","journal-title":"Angew. Chem., Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2022.114531_bib22","doi-asserted-by":"crossref","first-page":"13881","DOI":"10.1073\/pnas.2235848100","article-title":"The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance","volume":"100","author":"Rawat","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2022.114531_bib23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm1466","article-title":"Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid","volume":"12","author":"Vilch\u00e8ze","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114531_bib24","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1128\/AAC.46.7.2137-2144.2002","article-title":"Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis","volume":"46","author":"Nguyen","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib25","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"Unissa","year":"2016","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.ejmech.2022.114531_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119628","article-title":"Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: a systematic review","volume":"10","author":"Seifert","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114531_bib27","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1111\/bph.14867","article-title":"Isoniazid and host immune system interactions: a proposal for a novel comprehensive mode of action","volume":"176","author":"Khan","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114531_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions","volume":"56","author":"Kjellsson","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112362","article-title":"Designing new antitubercular isoniazid derivatives with improved reactivity and membrane trafficking abilities","volume":"144","author":"de Faria","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2022.114531_bib30","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1016\/j.ejmech.2009.05.009","article-title":"Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid","volume":"44","author":"Hearn","year":"2009","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127576","article-title":"Design and synthesis of 4-Aminoquinoline-isoindoline-dione-isoniazid triads as potential anti-mycobacterials","volume":"30","author":"Rani","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114531_bib32","article-title":"Biological and biochemical evaluation of isatin-isoniazid hybrids as bactericidal candidates against Mycobacterium tuberculosis","volume":"65","author":"Johansen Shalini","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib33","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1073\/pnas.0909133107","article-title":"Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents","volume":"107","author":"Zhou","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114531_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126810","article-title":"Synthesis, anti-plasmodial and cytotoxic evaluation of 1H-1,2,3-triazole\/acyl hydrazide integrated tetrahydro-\u03b2-carboline-4-aminoquinoline conjugates","volume":"30","author":"Sharma","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114531_bib35","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ejmech.2016.09.044","article-title":"4-Aminoquinoline-ferrocenyl-chalcone conjugates: synthesis and anti-plasmodial evaluation","volume":"125","author":"Singh","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib36","first-page":"204","article-title":"Treatment of biopsy and culture negative Mycobacterium marinum: diagnostic and therapeutic considerations","volume":"13","author":"Tenbrick","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"10.1016\/j.ejmech.2022.114531_bib37","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bmcl.2018.03.021","article-title":"Alkylated\/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: synthesis and anti-mycobacterial evaluation","volume":"28","author":"Shalini","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114531_bib38","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/351456a0","article-title":"New use of BCG for recombinant vaccines","volume":"351","author":"Stover","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114531_bib39","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2958.2002.03162.x","article-title":"Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis","volume":"46","author":"Larsen","year":"2002","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.ejmech.2022.114531_bib40","doi-asserted-by":"crossref","first-page":"16857","DOI":"10.1074\/jbc.M000569200","article-title":"Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis","volume":"275","author":"Kremer","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1054\/tuld.1998.0002","article-title":"Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update","volume":"79","author":"Ramaswamy","year":"1998","journal-title":"Tuber. Lung Dis."},{"key":"10.1016\/j.ejmech.2022.114531_bib42","article-title":"Heterologous expression of ethA and katG in Mycobacterium marinum enables the rapid identification of new prodrugs active against","volume":"65","author":"Ho","year":"2021","journal-title":"Mycobacterium tuberculosis, Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.micro.61.111606.122346","article-title":"The mechanism of isoniazid killing: clarity through the scope of genetics","volume":"61","author":"Vilch\u00e8ze","year":"2007","journal-title":"Annu. Rev. Microbiol."},{"key":"10.1016\/j.ejmech.2022.114531_bib44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.drudis.2016.09.009","article-title":"A new \u2018golden age\u2019 for the antitubercular target InhA","volume":"22","author":"Ro\u017eman","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2022.114531_bib45","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1128\/AAC.00266-11","article-title":"Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions","volume":"55","author":"Vilch\u00e8ze","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib46","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ardp.201600186","article-title":"Recent advances and structural features of enoyl-ACP reductase inhibitors of Mycobacterium tuberculosis","volume":"349","author":"Inturi","year":"2016","journal-title":"Arch. Pharm. (Weinheim)"},{"key":"10.1016\/j.ejmech.2022.114531_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239354","article-title":"InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis","volume":"15","author":"Flint","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114531_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115744","article-title":"Inhibition of Mycobacterium tuberculosis InhA: design, synthesis and evaluation of new di-triclosan derivatives","volume":"28","author":"Armstrong","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib49","doi-asserted-by":"crossref","first-page":"e02508","DOI":"10.1128\/AAC.02508-19","article-title":"KatG as counterselection marker for nontuberculous mycobacteria","volume":"64","author":"Gagliardi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib50","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/jac\/dkr566","article-title":"A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system","volume":"67","author":"Maruri","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2022.114531_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":"A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114531_bib52","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1016\/j.vaccine.2006.05.097","article-title":"Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis","volume":"24","author":"Sambandamurthy","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ejmech.2022.114531_bib53","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1101\/gr.075069.107","article-title":"Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis","volume":"18","author":"Stinear","year":"2008","journal-title":"Genome Res."},{"key":"10.1016\/j.ejmech.2022.114531_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005660","article-title":"Non mycobacterial virulence genes in the genome of the emerging pathogen Mycobacterium abscessus","volume":"4","author":"Ripoll","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2022.114531_bib55","series-title":"Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes","author":"Woods","year":"2011"},{"key":"10.1016\/j.ejmech.2022.114531_bib56","article-title":"Direct inhibitors of InhA are active against","volume":"7","author":"Manjunatha","year":"2015","journal-title":"Mycobacterium tuberculosis, Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114531_bib57","doi-asserted-by":"crossref","first-page":"17512","DOI":"10.1074\/jbc.RA119.010135","article-title":"A piperidinol-containing molecule is active against Mycobacterium tuberculosis by inhibiting the mycolic acid flippase activity of MmpL3","volume":"294","author":"Dupont","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114531_bib58","doi-asserted-by":"crossref","DOI":"10.1093\/bioinformatics\/bty560","article-title":"fastp: an ultra-fast all-in-one FASTQ preprocessor","volume":"34","author":"Chen","year":"2018","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ejmech.2022.114531_bib59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13059-019-1891-0","article-title":"Improved metagenomic analysis with Kraken 2","volume":"20","author":"Wood","year":"2019","journal-title":"Genome Biol."},{"key":"10.1016\/j.ejmech.2022.114531_bib60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J. Comput. Biol."},{"key":"10.1016\/j.ejmech.2022.114531_bib61","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/AAC.01063-06","article-title":"EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets","volume":"51","author":"Dover","year":"2007","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:43:27Z","timestamp":1759329807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":59,"alternative-id":["S0223523422004330"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114531","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114531"}}